Studies of catecholamine metabolism in Schizophrenia/Psychosis-II

James W. Maas, Salvador A. Contreras, Alexander L. Miller, Nancy Bennan, Charles L. Bowden, Martin A. Javors, Emiias Seleshi, Susan Weintraub

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Acutely psychotic schizophrenic patients were maintained on debrisoquin (DBQ) throughout 5 weeks of treatment with haloperidol. Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week. During haloperidol treatment, plasma levels of HVA tended to decrease, concurrent with increased renal cltlrance ofHVA. Plasma 3-methoxy-4-hydroxyphenyl-glycol (MHPG) levels and urinary MHPG output both decreased over the course of treatment. The differences in HVA and MHPG metabolism suggest differential effects of treatment on dopamine and norepinephrine systems. Neuroleptic treatment also abolished the marked morning decreases in plasma HVA concentrations (reported in part I).

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalNeuropsychopharmacology
Volume8
Issue number2
DOIs
StatePublished - Feb 1993

Keywords

  • Dopamine
  • HVA
  • MHPG
  • Neuroleptic actions
  • Norepinephrine
  • Psychosis
  • Renal clearance
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Studies of catecholamine metabolism in Schizophrenia/Psychosis-II'. Together they form a unique fingerprint.

  • Cite this

    Maas, J. W., Contreras, S. A., Miller, A. L., Bennan, N., Bowden, C. L., Javors, M. A., Seleshi, E., & Weintraub, S. (1993). Studies of catecholamine metabolism in Schizophrenia/Psychosis-II. Neuropsychopharmacology, 8(2), 111-116. https://doi.org/10.1038/npp.1993.12